Back to top
more

Editas Medicine (EDIT)

(Delayed Data from NSDQ)

$2.44 USD

2.44
1,622,130

-0.07 (-2.79%)

Updated Aug 1, 2025 03:59 PM ET

After-Market: $2.44 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth C Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (143 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Perrigo Company (PRGO) Q1 Earnings: Disappointment in Store?

by Zacks Equity Research

Perrigo Company plc (PRGO) is expected to report first-quarter 2017 results later this month.

    Zacks Equity Research

    4 Drug Stocks Poised to Beat this Earnings Season

    by Zacks Equity Research

    M&A and licensing deals as well as drug pricing issues are expected to remain in focus in 2017.

      Zacks Equity Research

      What's in Store for Immune Design (IMDZ) Stock in Q1 Earnings?

      by Zacks Equity Research

      Immune Design Corp (IMDZ) is expected to report first-quarter 2017 results on May 9.

        Zacks Equity Research

        What's in Store for BioDelivery (BDSI) this Earnings Season?

        by Zacks Equity Research

        BioDelivery Sciences International, Inc. (BDSI) is expected to report first-quarter 2017 results later this month. Last quarter, the company???s loss was wider than expected.

          Zacks Equity Research

          Teva Pharmaceutical (TEVA) Q1 Earnings: What's in the Cards?

          by Zacks Equity Research

          Teva Pharmaceutical Industries Ltd. (TEVA) is scheduled to report first-quarter 2017 earnings on May 11

            Zacks Equity Research

            Is Horizon Pharma (HZNP) Poised for a Beat in Q1 Earnings?

            by Zacks Equity Research

            Horizon Pharma plc (HZNP) is scheduled to report first-quarter 2017 results before the opening bell on May 8.

              Zacks Equity Research

              What's in the Cards for Allergan (AGN) this Earnings Season?

              by Zacks Equity Research

              Allergan plc (AGN) will be reporting first-quarter 2017 earnings result on May 9, before the market opens.

                Zacks Equity Research

                Arena Pharmaceuticals (ARNA) Q1 Earnings: What's in Store?

                by Zacks Equity Research

                Arena Pharmaceuticals, Inc. (ARNA) is expected to report first-quarter 2017 on May 9, after market closes.

                  Zacks Equity Research

                  Can Ligand (LGND) Spring a Surprise this Earnings Season?

                  by Zacks Equity Research

                  Ligand Pharmaceuticals Incorporated (LGND) is scheduled to report first-quarter 2017 results on May 9, after the market closes.

                    Zacks Equity Research

                    What to Expect from Epizyme (EPZM) This Earnings Season?

                    by Zacks Equity Research

                    Epizyme, Inc. (EPZM) is scheduled to report first-quarter 2017 results on May 8, before the opening bell.

                      Zacks Equity Research

                      What's in Store for Adverum (ADVM) in Q1 Earnings?

                      by Zacks Equity Research

                      Adverum Biotechnologies, Inc (ADVM) is expected to report first-quarter 2017 results later this month.

                        Zacks Equity Research

                        What's in Store for Catalyst (CPRX) Stock in Q1 Earnings?

                        by Zacks Equity Research

                        Catalyst Pharmaceuticals, Inc. (CPRX) is expected to report first-quarter 2017 results on May 11.

                          Zacks Equity Research

                          GW Pharmaceuticals (GWPH) Q2 Earnings: What to Expect?

                          by Zacks Equity Research

                          GW Pharmaceuticals plc (GWPH) is expected to report second-quarter fiscal 2017 results on May 4.

                            Zacks Equity Research

                            What's in the Cards for ACADIA (ACAD) this Earnings Season?

                            by Zacks Equity Research

                            ACADIA Pharmaceuticals Inc. (ACAD) is expected to report first-quarter 2017 results on May 4.

                              Zacks Equity Research

                              Agios Pharmaceuticals (AGIO) Q1 Earnings: What's in Store?

                              by Zacks Equity Research

                              Agios Pharmaceuticals, Inc. (AGIO) is scheduled to report first-quarter results on May 4 before market open.

                                Zacks Equity Research

                                Allergan (AGN) and Editas Tie Up to Treat Eye Diseases

                                by Zacks Equity Research

                                Allergan plc's (AGN), and Editas Medicine, Inc. (EDIT), entered into a strategic research and development agreement.

                                  Zacks Equity Research

                                  Editas Medicine (EDIT) Shares March Higher, Can It Continue?

                                  by Zacks Equity Research

                                  Editas Medicine, Inc. (EDIT) has been on the move lately as the stock has risen by 6.6% in the past four weeks, and it is currently trading well above its 20-Day SMA